Opinion
Docket No. 1657.
February 16, 2005
TRANSFER ORDER
This litigation presently consists of 148 actions pending in 41 federal districts and listed on the attached Schedule A. Before the Panel are two motions, pursuant to 28 U.S.C. § 1407, that taken together seek centralization for coordinated or consolidated pretrial proceedings of all but one of these actions. Plaintiff in one Eastern Louisiana action seeks centralization of this litigation in the Eastern or Western Districts of Louisiana. Defendant Merck Co., Inc. (Merck) moves for centralization of this litigation in either the District of Maryland, the Southern District of Indiana, or the Northern District of Illinois. Merck also agrees with some plaintiffs that the District of New Jersey would be an appropriate transferee district. AmerisourceBergen Corp., a wholesaler defendant, supports centralization in the Maryland district. Most responding plaintiffs agree that centralization is appropriate, although some plaintiffs suggest alternative transferee districts, including the Northern District of Alabama, the Central or Northern Districts of California, the District of Delaware, the Southern District of Illinois, the District of Minnesota, the Eastern District of Missouri, the District of New Jersey, the Eastern or Southern Districts of New York, the Northern or Southern Districts of Ohio, the Western District of Oklahoma, the Eastern District of Pennsylvania, and the Southern or Western Districts of Texas.
Included in the Section 1407 motions were eleven additional actions pending in the Central District of California (2), the Southern District of California (1), the Southern District of Illinois (2), the Southern District of Indiana (1), the Western District of Missouri (1), the Southern District of New York (1), the Northern District of Texas (1), and the Southern District of Texas (2). These actions have been either remanded to their respective state courts, voluntarily dismissed, or otherwise closed. Accordingly, inclusion of the actions in Section 1407 proceedings is moot.
One other action — Teamsters Local 237 Welfare Fund, et al. v. Merck Co., Inc., S.D. New York, C.A. No. 1:04-9248 — was not included on either MDL-1657 motion and is now included in this transfer order. All parties to this action had notice of the proceedings before the Panel relating to Section 1407 centralization and had an opportunity to participate in those proceedings by stating their respective positions in writing and during the Panel's hearing session.
The Panel has been notified of nearly 300 potentially related actions pending in multiple federal districts. In light of the Panel's disposition of this docket, these actions will be treated as potential tag-along actions. See Rules 7.4 and 7.5, R.P.J.P.M.L., 199 F.R.D. 425, 435-36 (2001).
The three arguments in opposition to Section 1407 centralization can be summarized as follows: plaintiffs in two actions oppose inclusion of their actions in MDL-1657 proceedings, because motions to remand their actions to state court are pending; plaintiffs in some Southern Texas actions along with plaintiffs in one third-party payor action pending in the Southern District of New York oppose these actions' inclusion in MDL-1657, arguing that individual questions of fact in their actions predominate over any common questions of fact and/or that discovery is already underway in these actions; and plaintiffs in one action pending in the Eastern District of New York oppose inclusion of their action in 1407 proceedings, since it involves additional claims relating to a different prescription medication not involved in other MDL-1657 actions.
On the basis of the papers filed and hearing session held, the Panel finds that the actions in this litigation involve common questions of fact, and that centralization under Section 1407 in the Eastern District of Louisiana will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All actions focus on alleged increased health risks (including heart attack and/or stroke) when taking Vioxx, an anti-inflammatory drug, and whether Merck knew of these increased risks and failed to disclose them to the medical community and consumers. Centralization under Section 1407 is necessary in order to eliminate duplicative discovery, avoid inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary.
The pendency of a motion to remand to state court is not a sufficient basis to avoid inclusion in Section 1407 proceedings. We note that motions to remand in two actions, one action each in the District of Kansas and the Eastern District of Missouri, as well as in any other MDL-1657 actions can be presented to and decided by the transferee judge. See, e.g., In re Ivy, 901 F.2d 7 (2d Cir. 1990); In re Prudential Insurance Company of America Sales Practices Litigation, 170 F.Supp.2d 1346, 1347-48 (J.P.M.L. 2001).
Nor are we persuaded by the arguments of some opposing Texas plaintiffs and the New York third-party payor plaintiffs. We point out that transfer under Section 1407 has the salutary effect of placing all actions in this docket before a single judge who can formulate a pretrial program that: 1) allows discovery with respect to any non-common issues to proceed concurrently with discovery on common issues, In re Joseph F. Smith Patent Litigation, 407 F.Supp. 1403, 1404 (J.P.M.L. 1976); and 2) ensures that pretrial proceedings will be conducted in a manner leading to the just and expeditious resolution of all actions to the overall benefit of the parties. We note that the MDL-1657 transferee court can employ any number of pretrial techniques — such as establishing separate discovery and/or motion tracks — to efficiently manage this litigation. In any event, we leave the extent and manner of coordination or consolidation of these actions to the discretion of the transferee court. In re Mutual Funds Investment Litigation, 310 F.Supp.2d 1359 (J.P.M.L. 2004). It may be, on further refinement of the issues and close scrutiny by the transferee judge, that some claims or actions can be remanded to their transferor districts for trial in advance of the other actions in the transferee district. But we are unwilling, on the basis of the record before us, to make such a determination at this time. Should the transferee judge deem remand of any claims or actions appropriate, procedures are available whereby this may be accomplished with a minimum of delay. See Rule 7.6, 199 F.R.D. at 436-38. We are confident in the transferee judge's ability to streamline pretrial proceedings in these actions, while concomitantly directing the appropriate resolution of all claims.
The Panel is persuaded, however, that claims involving a prescription drug other than Vioxx in one Eastern District of New York action do not share sufficient questions of fact with claims relating to Vioxx to warrant inclusion of these non-Vioxx claims in MDL-1657 proceedings.
Given the geographic dispersal of constituent actions and potential tag-along actions, no district stands out as the geographic focal point for this nationwide docket. Thus we have searched for a transferee judge with the time and experience to steer this complex litigation on a prudent course. By centralizing this litigation in the Eastern District of Louisiana before Judge Eldon E. Fallon, we are assigning this litigation to a jurist experienced in complex multidistrict products liability litigation and sitting in a district with the capacity to handle this litigation.
IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, the actions listed on the attached Schedule A and pending outside the Eastern District of Louisiana are transferred to the Eastern District of Louisiana and, with the consent of that court, assigned to the Honorable Eldon E. Fallon for coordinated or consolidated pretrial proceedings with the actions pending there and listed on Schedule A.
IT IS FURTHER ORDERED that claims in Dominick Cain, et al. v. Merck Co., Inc., et al., E.D. New York, C.A. No. 1:01-3441, against Pharmacia Corp., Pfizer Inc., and G.D. Searle Co. relating to a prescription medication other than Vioxx are simultaneously separated and remanded to the Eastern District of New York.
SCHEDULE A
MDL-1657 — In re Vioxx Products Liability Litigation Middle District of Alabama Paul Turner, Sr. v. Merck Co., Inc., C.A. No. 1:04-999Danny M. Wilson v. Merck Co., Inc., C.A. No. 2:03-844
Northern District of Alabama Carolyn O. Hensley, etc. v. Merck Co., Inc., C.A. No. 1:03-906
William Cook v. Merck Co., Inc., et al., C.A. No. 2:02-2710
Sharon Scott Jones v. Merck Co., Inc., C.A. No. 5:04-3079
Southern District of Alabama Carolyn Younge, etc. v. Merck Co., Inc., et al., C.A. No. 1:03-125
Eastern District of Arkansas Linda Sue Otts v. Merck Co., Inc., C.A. No. 5:04-57
Western District of Arkansas Bobby Brown, et al. v. Merck Co., et al., C.A. No. 4:04-4140
Arthur Fulton, etc. v. Merck Co., Inc., C.A. No. 6:03-6107
Central District of California Charles Ashman v. Merck Co., Inc., C.A. No. 2:04-8225
Janet Briggs v. Merck Co., Inc., C.A. No. 2:04-9275
Northern District of California Kathy Tokes v. Merck Co., Inc., C.A. No. 3:04-4435
Patricia A. Taylor v. Merck Co., Inc., C.A. No. 3:04-4510
Jeffrey Brass v. Merck Co., Inc., C.A. No. 3:04-4521
Middle District of Florida Frances Dunleavey, et al. v. Merck Co., Inc., C.A. No. 2:04-539
Northern District of Florida Benjamin Burt, et al. v. Merck Co., Inc., C.A. No. 3:04-388
Southern District of Florida Ellen B. Gerber, et al. v. Merck Co., Inc., C.A. No. 0:04-61429
Josefa Abraham, et al. v. Merck Co., Inc., C.A. No. 1:04-22631
Sidney Schneider v. Merck Co., Inc., et al., C.A. No. 1:04-22632
Clara Fontanilles v. Merck Co., Inc., C.A. No. 1:04-22799
Stanley Silber, et al. v. Merck Co., Inc., C.A. No. 9:04-80983
Northern District of Georgia Richard Zellmer v. Merck Co., Inc., et al., C.A. No. 1:03-2530
Edna Strickland v. Merck Co., Inc., C.A. No. 1:04-3231
Northern District of Illinois
Linda Grant, et al. v. Merck Co., Inc., C.A. No. 1:04-6407Constance Oswald v. Merck Co., Inc., C.A. No. 1:04-6741
Anita Ivory v. Merck Co., Inc., C.A. No. 1:04-7218
Southern District of Illinois Roberta Walson, etc. v. Merck Co., Inc., C.A. No. 3:04-27
John Ellis v. Merck Co., Inc., et al., C.A. No. 3:04-792
Bilbrey v. Merck Co., Inc., C.A. No. 3:04-836
Southern District of Indiana Estate of Lowell D. Morrison v. Merck Co., Inc., C.A. No. 1:03-1535
Kimberly Van Jelgerhuis, et al. v. Merck Co., Inc., C.A. No. 1:04-1651
District of Kansas Vicky Hunter v. Merck Co., Inc., C.A. No. 2:04-2518
Betty S. Smith v. Merck Co., Inc., C.A. No. 6:04-1355
Eastern District of Kentucky Daniel K. Williams v. Merck Co., Inc., C.A. No. 2:04-235
Richard J. Getty, et al. v. Merck Co., Inc., C.A. No. 5:04-452
Eastern District of Louisiana Salvadore Christina, Sr. v. Merck Co., Inc., C.A. No. 2:04-2726
Angelis Alexander v. Merck Co., Inc., C.A. No. 2:04-2845
Leonce Davis v. Merck Co., Inc., C.A. No. 2:04-2937
Mary V. Gagola v. Merck Co., Inc., C.A. No. 2:04-3053
Christine L. Parr v. Merck Co., Inc., C.A. No. 2:04-3054
Clifton Adam Savage, Sr. v. Merck Co., Inc., C.A. No. 2:04-3055
Delores Thomas Robertson v. Merck Co., Inc., C.A. No. 2:04-3056
Howard Mark Falick v. Merck Co., Inc., C.A. No. 2:04-3060
Warren L. Gottsegen, M.D. v. Merck Co., Inc., C.A. No. 2:04-3065
Middle District of Louisiana Michael Wayne Russell v. Merck Co., Inc., C.A. No. 3:04-712
Linda Kay Hudson v. Merck Co., Inc., C.A. No. 3:04-776
Jesse Wilkinson v. Merck Co., Inc., C.A. No. 3:04-800
Wilson Brown v. Merck Co., Inc., C.A. No. 3:04-801
Dorothy Bracken v. Merck Co., Inc., C.A. No. 3:04-802
James Edward Benoit v. Merck Co., Inc., C.A. No. 3:04-803
Clarence Chiszle v. Merck Co., Inc., C.A. No. 3:04-804
Western District of Louisiana Anthony J. Mallet, et al. v. Merck Co., Inc., et al., C.A. No. 2:02-2304
Calvin Warren, et al. v. Merck Co., Inc., C.A. No. 3:04-2110
Vicki White v. Merck Co., Inc., C.A. No. 3:04-2126
Norma Merrit, et al. v. Merck Co., Inc., C.A. No. 5:03-1401
Herchial Wright, et al. v. Merck Co., Inc., C.A. No. 5:04-2268
Leroy Bates, et al. v. Merck Co., Inc., C.A. No. 5:04-2269
Vaughn McKnight v. Merck Co., Inc., C.A. No. 5:04-2270
Josephine Harper v. Merck Co., Inc., C.A. No. 5:04-2271
Lendell Burns, et al. v. Merck Co., Inc., C.A. No. 5:04-2272
Leona Sadler v. Merck Co., Inc., C.A. No. 5:04-2273
William Tice, et al. v. Merck Co., Inc., C.A. No. 5:04-2274Maynard Butler, et al. v. Merck Co., Inc., C.A. No. 5:04-2275
Marion Evans, et al. v. Merck Co., Inc., C.A. No. 5:04-2276
Donna Lavergne v. Merck Co., Inc., C.A. No. 6:04-2174
District of Maryland Lindsey Edler, etc. v. Merck Co., Inc., C.A. No. 1:03-3612
Melvin Biles v. Merck Co., Inc., C.A. No. 1:04-975
David Morris, Jr. v. Merck Co., Inc., C.A. No. 8:04-3024
Daniel Martin Jeffers, et al. v. Merck Co., Inc., C.A. No. 8:04-3604
District of Massachusetts Frank R. Saia v. Merck Co., Inc., C.A. No. 1:04-12166
District of Minnesota Carolyn Y. Glover v. Merck Co., Inc., C.A. No. 0:03-5166
Lowell Burris, Jr. v. Merck Co., Inc., C.A. No. 0:04-4375
Shirley Homister v. Merck Co., Inc., C.A. No. 0:04-4754
Northern District of Mississippi Frances Shannon, et al. v. Merck Co., Inc., et al., C.A. No. 2:03-105
Southern District of Mississippi Leona McFarland, et al. v. Merck Co., Inc., et al., C.A. No. 2:03-247
Bettye J. Magee, et al. v. Merck Co., Inc., et al., C.A. No. 2:03-249
Jerry Melton v. Merck Co., Inc., et al., C.A. No. 2:04-372
Janet Sue Morgan, et al. v. Merck Co., Inc., et al., C.A. No. 3:03-435
Brenda Price, et al. v. Merck Co., Inc., et al., C.A. No. 3:04-866
Eastern District of Missouri Deyonne E. Whitmore v. Merck Co., Inc., C.A. No. 4:03-1354
Janice Perkins v. Merck Co., Inc., C.A. No. 4:04-1446
Jurhee Bench v. Merck Co., Inc., C.A. No. 4:04-1447
Western District of Missouri Caroline Nevels v. Merck Co., Inc., et al., C.A. No. 4:04-952
Russell Young, etc. v. Merck Co., C.A. No. 6:04-5117
District of New Jersey Patrick Besaw v. Merck Co., Inc., C.A. No. 3:04-5178
Brenda Aguero, et al. v. Merck Co., Inc., C.A. No. 3:04-5341
Eastern District of New York Dominick Cain, et al. v. Merck Co., Inc., et al., C.A. No. 1:01-3441
William Hanson v. Merck Co., Inc., C.A. No. 1:04-2949
Jerome Covington v. Merck Co., Inc., C.A. No. 1:04-4439
Alan Mell v. Merck Co., Inc., C.A. No. 1:04-4606
Lorraine Fialo v. Merck Co., Inc., C.A. No. 1:04-4686
Lawrence Wright, et al. v. Merck Co., Inc., C.A. No. 2:04-4485
William Fontanetta, et al. v. Merck Co., Inc., C.A. No. 2:04-4486
Southern District of New York Laney C. Davis v. Merck Co., Inc., C.A. No. 1:04-8082
Elizabeth Aiken v. Merck Co., Inc., C.A. No. 1:04-8085
Walter McNaughton v. Merck Co. Inc., C.A. No. 1:04-8297Carmen M. Pagan, et al. v. Merck Co., Inc., C.A. No. 1:04-8959
Teamsters Local 237 Welfare Fund, et al. v. Merck Co., Inc., C.A. No. 1:04-9248
Anna Quick v. Merck Co., Inc., C.A. No. 7:04-8169
Northern District of Ohio Marjory Knoll v. Merck Co., Inc., C.A. No. 1:04-2209
Danford K. Jones, et al. v. Merck Co., Inc., C.A. No. 1:04-2217
Meadows, et al. v. Merck Co., Inc., C.A. No. 1:04-2229
Wanda Moldovan, et al. v. Merck Co., Inc., C.A. No. 1:04-2245
Janet Dauterman, et al. v. Merck Co., Inc., C.A. No. 3:03-7623
Western District of Oklahoma Paul E. House v. Merck Co., Inc., C.A. No. 5:04-1235
Eastern District of Pennsylvania Henry Smith, et al. v. Merck Co., Inc., C.A. No. 2:04-4713
Michelle Donovan v. Merck Co., Inc., C.A. No. 2:04-4882
Gwendolyn L. Carr v. Merck Co., Inc., C.A. No. 2:04-4900
Fred S. Engle v. Merck Co., Inc., C.A. No. 2:04-5077
Merrick Sirota, et al. v. Merck Co., Inc., C.A. No. 2:04-5130
District of Puerto Rico Rafael Gonzalez-Arias, et al. v. Merck Co., Inc., C.A. No. 3:04-2263
District of South Carolina Bridget Elaine Michaud, etc. v. Merck Co., Inc., C.A. No. 4:03-3083
Eastern District of Texas Arthur Clifford Hall, et al. v. Merck Co., Inc., C.A. No. 1:04-684
Brenda Lewis, et al. v. Merck Co., Inc., C.A. No. 1:04-685
Billie Painton, et al. v. Merck Co., Inc., C.A. No. 1:04-686
Lovincy Richard, et al. v. Merck Co., Inc., et al., C.A. No. 1:04-703
Bill Jolley, et al. v. Merck Co., Inc., C.A. No. 2:04-376
Marian Williamson, etc. v. Merck Co., Inc., C.A. No. 2:04-406
Deborah Daley, etc. v. Merck Co., Inc., et al., C.A. No. 6:03-509
Northern District of Texas Dellas Staples, et al. v. Merck Co., Inc., et al., C.A. No. 3:03-180
Michael R. Leonard v. Merck Co., Inc., C.A. No. 3:04-2157
Jack A. Register, et al. v. Merck Co., Inc., et al., C.A. No. 3:04-2259
Southern District of Texas Heirs of the Estate of Pablo Flores v. Merck Co., Inc., et al., C.A. No. 2:03-362
Audona Sandoval v. Merck Co., Inc., C.A. No. 2:04-544
Jeffrey L. Denny, et al. v. Merck Co., Inc., et al., C.A. No. 3:04-526
Kimberly D. Stubblefield, etc. v. Merck Co., Inc., et al., C.A. No. 4:02-3139
John P. Eberhardt v. Merck Co., Inc., C.A. No. 4:03-1380
Myrtle Louise Bell, et al. v. Merck Co., Inc., et al., C.A. No. 4:03-3448
Thomas Joseph Pikul, etc. v. Merck Co., Inc., et al., C.A. No. 4:03-3656
Opalene Stringer, et al. v. Merck Co., Inc., et al., C.A. No. 4:03-3657
Reginald K. Fears v. Merck Co., Inc., C.A. No. 4:04-4187Peggy J. Balch v. Merck Co., Inc., C.A. No. 4:04-4201
John R. Stout v. Merck Co., Inc., C.A. No. 4:04-4205
Charles C. Gilmore v. Merck Co., Inc., C.A. No. 4:04-4206
Johnny White v. Merck Co., Inc., C.A. No. 4:04-4207
Donna Hale v. Merck Co., Inc., C.A. No. 4:04-4208
Bernadette Young v. Merck Co., Inc., C.A. No. 4:04-4209
William B. Gregory, Jr. v. Merck Co., Inc., C.A. No. 4:04-4327
Patricia Benavides, etc. v. Merck Co., Inc., et al., C.A. No. 5:03-134
Patricia Benavides, etc. v. Merck Co., Inc., et al., C.A. No. 5:04-153
Olga Sanchez v. Merck Co., Inc., et al., C.A. No. 7:04-352
Maria Emma Hinojosa v. Merck Co., Inc., C.A. No. 7:04-373
Western District of Texas Joe Hopson, etc. v. Merck Co., Inc., et al., C.A. No. 1:04-485
Larry Lee Bauman, et al. v. Merck Co., Inc., C.A. No. 1:04-707
Carolyn Reed, etc. v. Minor, et al., C.A. No. 1:04-731
District of Utah Della Jo Salt, et al. v. Merck Co., Inc., C.A. No. 2:01-794
District of Vermont Sara Cheeseman v. Merck Co., Inc., C.A. No. 1:04-261
Western District of Virginia Catherine Wheatley, etc. v. Merck Co., Inc., et al., C.A. No. 2:04-20